Search clinical trials for: Durvalumab; MEDI4736

Total 738 results

Italian Network for Tumor Biotherapy Foundation
AstraZeneca

Unknown

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Peritoneal Mesothelioma | Pleural Mesothelioma

Italy
Academic Thoracic Oncology Medical Investigators...
AstraZeneca

Completed

A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients

Non-Small Cell Lung Cancer NSCLC

United States
NSABP Foundation Inc

Completed

Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer

Rectal Cancer

United States
AstraZeneca

Completed

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)

Advanced Solid Malignancies

United States, Germany, Italy, United Kingdom, Canada, France, Korea, Republic of, Netherlands
Grupo Espanol Multidisciplinario del Cancer Digestivo
AstraZeneca; Vall d'Hebron Institute of Oncology (VHIO)

Recruiting

Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (DUREC)

Rectal Cancer

Spain
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Active, not recruiting

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Thyroid Cancer

United States
Swiss Group for Clinical Cancer Research

Active, not recruiting

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (SAKK 06/17)

Urothelial Cancer

Germany, Switzerland
NSABP Foundation Inc

Completed

Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy

Colorectal Cancer Metastatic

United States
Peregrine Pharmaceuticals

Withdrawn

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

Non-Small Cell Lung Cancer
Swiss Group for Clinical Cancer Research

Completed

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

NSCLC Non-small Cell Lung Cancer

Switzerland
Vastra Gotaland Region
AstraZeneca

Recruiting

Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736) (ASTEROID)

NSCLC, Stage I

Finland, Norway, Sweden
AstraZeneca

Completed

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy (DUART)

Non-small Cell Lung Cancer

Italy, Poland, France, Spain, United States, Russian Federation
Swiss Group for Clinical Cancer Research

Active, not recruiting

1st Line Durvalumab in PS 2 NSCLC Patients

NSCLC Stage IV | NSCLC Stage IIIB

Switzerland
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Completed

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Washington University School of Medicine
AstraZeneca

Terminated

MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors

Kidney Cancer | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Cancer of the Ovary | Renal Cancer | Colorectal Carcinoma | Ovary Cancer | Cancer of Breast | Gastroesophageal Cancer | Cancer of the Pancreas | Cancer of the Breast | Cancer... and other conditions

United States
AstraZeneca

Completed

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC) (MERMAID-1)

Carcinoma, Non-Small-Cell Lung

United States, Canada, Denmark, France, Netherlands, Belgium, Poland, Taiwan, Thailand, Vietnam, Italy, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Russian Federation, Germany, Hong Kong, Spain, Greece, Switzerland, Australia, Isra... and more
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
AstraZeneca
Parexel; Iqvia Pty Ltd; Medidata Solutions; CISCRP

Active, not recruiting

Durvalumab Long-Term Safety and Efficacy Study (WAVE)

Solid Tumor

Spain, United Kingdom, United States, Canada, Czechia, Poland, Romania, Thailand, Vietnam, Belgium, France, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Malaysia, Taiwan, Australia, Germany, Turkey, Ukraine, Nethe... and more
AstraZeneca

Completed

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United Kingdom, United States, Italy, Spain, Germany, France
Shadia Jalal, MD
AstraZeneca; MedImmune LLC; Big Ten Cancer Research Consortium

Completed

A Study of Durvalumab (MEDI4736) in Esophageal Cancer

Esophageal Cancer

United States
PrECOG, LLC.
AstraZeneca

Completed

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505)

Mesothelioma | Pleural Mesothelioma

United States
Groupe Oncologie Radiotherapie Tete et Cou
UNICANCER; Center Eugene Marquis

Active, not recruiting

Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN (REWRITe)

HNSCC

France
Intergroupe Francophone de Cancerologie Thoracique

Terminated

Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer (IONESCO)

Carcinoma, Non-Small-Cell Lung

France
Spanish Lung Cancer Group

Completed

Durvalumab in Solid Tumors

Cancer | HIV

Spain
MedImmune LLC

Completed

A Phase 1/2 Study to Evaluate MEDI4736

Advanced Solid Tumors

United States, Germany, Italy, United Kingdom, Belgium, Canada, Korea, Republic of, Taiwan, France
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

United States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
Immunocore Ltd
AstraZeneca

Completed

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Malignant Melanoma

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca

Completed

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

Metastatic Anaplastic Thyroid Cancer

United States
Tae Won Kim

Terminated

The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors

Colorectal Cancer | Solid Tumor

Korea, Republic of
Celgene

Completed

A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005)

Multiple Myeloma

United States, Spain, Austria, Greece, Netherlands, Sweden
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)

Non-Small Cell Lung Cancer

United States, Belgium, France, Italy, Spain, United Kingdom, Canada, Hungary, Poland, Thailand, Germany, Korea, Republic of, Czechia, Japan, Philippines, Taiwan, Singapore, Austria
Simon C Pacey, MD
AstraZeneca

Active, not recruiting

Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab (CALIBRATION)

Oesophageal Cancer

United Kingdom
Fundación GECP

Completed

Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy. (S-REAL)

Small Cell Lung Cancer (SCLC)

Spain
Hellenic GenitoUrinary Cancer Group

Active, not recruiting

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Bladder Cancer

Greece
AstraZeneca

Active, not recruiting

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Melanoma | Cervical Cancer | Small Cell Lung Cancer | Triple Negative Breast Neoplasms | Advanced Solid Tumours | Non-Small-Cell Lung Cancer | Gastroesophageal Cancer | Clear Cell Renal Cell Cancer | Squamous Cell Cancer of Head and Neck

United States, Spain, Canada, France
AstraZeneca

Active, not recruiting

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (PACIFIC-5)

Carcinoma, Non-Small-Cell Lung

Poland, Taiwan, India, Mexico, Russian Federation, Turkey, China, Korea, Republic of, Philippines, Hong Kong
Rush University Medical Center
AstraZeneca

Recruiting

Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC (ESR1814205)

Stage III Non-small-cell Lung Cancer

United States
AstraZeneca

Completed

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)

Carcinoma, Non- Small Cell Lung

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Poland, Taiwan, Vietnam, Korea, Republic of, Brazil, Czechia, Hungary, Japan, Peru, Russian Federation, Hong Kong, Israel, Greece, Australia, Singapore, Turkey, India, A...
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC)

Non-Small Cell Lung Cancer

United States, Belgium, France, Germany, Italy, Spain, Canada, Poland, Thailand, Vietnam, Korea, Republic of, Hungary, Japan, Mexico, Peru, Turkey, United Kingdom, Taiwan, Chile, Australia, Israel, South Africa, Netherlands, Greece, Sin... and more
Incyte Corporation
AstraZeneca

Completed

A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

Head and Neck Cancer | Lung Cancer | Solid Tumors | UC (Urothelial Cancer)

United States
Baylor College of Medicine

Completed

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Mesothelioma

United States
Leo Mascarenhas

Completed

Durvalumab in Pediatric and Adolescent Patients

Lymphoma | Solid Tumor | Central Nervous System Tumors

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Completed

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Metastatic Colorectal Cancer

United States
AstraZeneca

Recruiting

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma (TREMENDOUS)

Hepatocellular Carcinoma

China
Grupo Espanol de Tumores Neuroendocrinos
MFAR

Active, not recruiting

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)

Metastatic Thyroid Cancer | Metastatic Thyroid Papillary Carcinoma | Metastatic Thyroid Follicular Carcinoma

Spain
Advaxis, Inc.
MedImmune LLC

Terminated

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

Cervical Cancer | Cancer | Head and Neck Cancer

United States
Memorial Sloan Kettering Cancer Center
Celgene Corporation

Withdrawn

A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma

Solitary Bone Plasmacytoma

United States
MedImmune LLC

Completed

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma

Canada, United States, Taiwan, Korea, Republic of, Japan, Singapore
Eli Lilly and Company
AstraZeneca

Completed

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Metastatic Pancreatic Cancer

Spain, United States, Korea, Republic of, France, Italy
Weill Medical College of Cornell University
AstraZeneca

Completed

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States

Search clinical trials for: Durvalumab; MEDI4736

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations